Table 2.

Individual AGREE II domain results for each cancer therapy-induced neuropathy guideline.

Guideline title	Scope and purpose	Stakeholder involvement	Rigour of development	Clarity of presentation	Applicability	Editorial independence	Overall assessment	Recommendation
Neuropathic pain - pharmacological management	88.90%	73.30%	60%	86.60%	60%	51.70%	85	Strongly recommended
Peripheral neuropathy	55.50%	63.30%	41.70%	94.40%	49.20%	45%	58	Weakly recommended
Neuropathic pain guideline	51.10%	26.60%	33.30%	85.50%	37.50%	11.60%	50	Weakly recommended
Median domain score	55.50%	63.30%	41.70%	86.60%	49.20%	45%	58	-